A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy

Epilepsia

Volumn 46, Issue 7, 2005, Pages 1046-1054

  Mimrod, Dorit ^a   Specchio, Luigi M ^b   Britzi, Malka ^a,c   Perucca, Emilio ^d   Specchio, Nicola ^e,f   Neve, Angela La ^e   Soback, Stefan ^c   Levy, René H ^g   Gatti, Giuliana ⁱ   Doose, Dennis R ^h,i   Maryanoff, Bruce E ^h,i   Bialer, Meir ^a,j  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF FOGGIA   (Italy)

^c KIMRON VETERINARY INSTITUTE   (Israel)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g UNIVERSITY OF WASHINGTON   (United States)

^h JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

ⁱ NONE

^j HEBREW UNIVERSITY OF JERUSALEM   (Israel)

more..

Author keywords

Carbamazepine; Drug interaction; Enzyme induction; Metabolism; Pharmacokinetics; Topiramate; Valproic acid

Indexed keywords

10 HYDROXYTOPIRAMATE; 2,3 O DESISOPROPYLIDENE TOPIRAMATE; 9 HYDROXYTOPIRAMATE; ACETYLSALICYLIC ACID; CARBAMAZEPINE; DRUG METABOLITE; ETIRACETAM; LAMOTRIGINE; LANSOPRAZOLE; TOPIRAMATE; TOPIRAMATE 2,3 DIOL; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG OXIDATION; DRUG URINE LEVEL; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; VALPROIC ACID;

EID: 21844447569     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.06805.x     Document Type: Article

References (27)

1. Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Clin Pharmacokinet 1997;54:752-73.
2. Privitera MD, Twyman RE. Topiramate: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:740-52.
3. Kamin M, Topiramate: clinical efficacy and use in nonepileptic disorders. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:753-9.
4. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat conference on new antiepileptic drugs (EILAT VII). Epilepsy Res 2004;61:1-48.
5. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004;12:763-80.
6. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-80.
7. Doose DR, Brodie M, Wilson EA, et al. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epileptic patients. Epilepsia 2003;44:917-22.
8. Doose DR, Walker SA, Pledger G, et al. Evaluation of phenobarbital and primidone/phenobarbital (primidone active metabolite) plasma concentration during administration of add-on topiramate therapy in five multicenter, double-blind, placebo controlled trials in outpatients with partial seizures. Epilepsia 1995;36(suppl 3):158.
9. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steadysate pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997;38:324-33.
10. Sachdeo RC, Sachdeo SK, Levy RH. et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 2002;43:691.
11. Doose DL, Streeter AJ. Topiramate: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:727-4.
12. Britzi M, Soback S, Isoherranen N, et al. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther Drug Monit 2003;25:314-22.
13. Britzi M, Perucca E, Soback S, et al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the presence and absence of enzyme induction by carbamazepine. Epilepsia 2005;46:378-84.
14. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978;6:547-8.
15. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982.
16. Rowland M, Tozer T. Clinical pharmacokineiics, 3rd ed. Baltimore: Williams & Wilkins, 1995.
17. Ferrari AR, Guerrini R, Gatti G, et al. Influence of dosage, age and comedication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit 2003;25:700-8.
18. Battino D, Croci D. Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet 2005;44:407-16.
19. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo controlled dose-ranging trial in refractory partial epilepsy using 200-, 400- and 600 mg daily dosages. Neurology 1996;46:1684-90.
20. Adin J, Gomez MC, Blanco Y, et al. Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther Drug Monit 2004;26:251-7.
21. Contin M, Riva R, Albani F, et al. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 2002;24:332-7.
22. Nortey SO, Wu WN, Maryanoff BE. Synthesis of hydroxylated derivatives of topiramate, a novel antiepileptic drug based on D-fructose: investigation of oxidative metabolites. Carbohydrate Res 1997;304:29-38.
23. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 2004;76:192-200.
24. Sills GI, Kwan P, Butler E, et al. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002;3:427-32.
25. May WT, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age and comedication. Epilepsia 2002;24:366-74.
26. Wu WN, McKown LA. Recent advances in biotransformation of CNS and cardiovascular agents. Curr Drug Metab 2000;1:255-70.
27. Maryanoff BE, Nortey SO, Gardocki JF, et al. Anticonvulsant O-alkylsulfamates. 2,3:4,5-bis-0-(1-methylethlidene)-β-D-fructopyranose- sulfamate and related compounds. J Med Chem 1987;30:880-7.